-
A Guest Perspective for Gratitude Day: Why Huntington’s Disease May Be Neuroscience’s Best Investment
Latest News
-
New results bring BDNF therapies into focus
Some unexpected findings suggest new ways to aim at an old target in HD
-
2CARE study of coenzyme Q for Huntington's disease ends in disappointment
The largest ever HD drug trial, testing coenzyme Q10, is halted for 'futility'. What does that mean for HD research?
-
A starring role for astrocytes in Huntington's disease?
Brain cells called astrocytes might play a bigger role than previously thought in Huntington's disease
-
HD mice provide a useful failure
Can drug trials that fail be helpful? A HD mouse study provides solid evidence of an approach that doesn't help HD
-
Illuminating the progression of Huntington’s disease
Researchers have used mice with glowing brain cells to decipher the first steps of neurodegeneration
-
Jumping genes: Huntington's disease protein invades brain transplants
A long-term study of the brains of HD patients who received grafts of fetal tissue reveals a surprising result
-
The brain in Huntington's disease: greater than the sum of its parts?
An important new study asks the question: what parts of the brain might need most help in HD?
-
NUB1: enhancing clearance to decrease mutant huntingtin
NUB1 increases mutant huntingtin removal from cells, reducing the toxic effects of HD in fruit flies
-
Could HD be caused by amino acid deficiency?
Does a specific amino acid deficiency contribute to the development of HD?
-
Raptor announces results of cysteamine trial for Huntington's disease
Raptor Pharmaceuticals announces intermediate results from a long-term study of cysteamine in Huntington's disease
HDBuzz Trial Tracker
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
Additional insights from Phase 2 study results and update on plans for Phase 3 trial for votoplam
